Trulicity and Metformin Together: Why the Combination Outperforms Monotherapy and the Protocol to Use Both Safely

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Trulicity (dulaglutide) and metformin target different metabolic pathways, creating additive A1C reduction of 1.8 to 2.4% versus 1.2 to 1.5% for either drug alone
• The combination reduces hypoglycemia risk compared to insulin-based regimens while producing comparable glycemic control
• Metformin does not interfere with Trulicity's weight-loss effect and may enhance it through complementary mechanisms
• About 68% of patients starting Trulicity are already on metformin, making this the most common GLP-1 combination in clinical practice

Direct answer (40-60 words)

Trulicity and metformin work through different mechanisms (GLP-1 receptor activation versus AMPK pathway modulation) and can be safely combined. Clinical trials show the combination reduces A1C by 1.8 to 2.4 percentage points versus 1.2 to 1.5% for either alone. No significant drug-drug interaction exists, though GI side effects may overlap during titration.

Table of contents

1. The mechanism: why two pathways beat one
2. The clinical evidence for combination therapy
3. What most articles get wrong about the interaction
4. The dosing protocol: when to start both versus sequential addition
5. Side effects: which are additive and which are not
6. The weight-loss question: does metformin help or hurt Trulicity's effect?
7. Insurance and cost considerations for dual therapy
8. When NOT to combine Trulicity and metformin
9. The decision tree: choosing your second agent
10. Metformin formulations and which works best with GLP-1s
11. Monitoring requirements for combination therapy
12. FAQ

The mechanism: why two pathways beat one

Trulicity (dulaglutide) is a GLP-1 receptor agonist. It works by:

• Stimulating insulin secretion in response to meals (glucose-dependent, so low hypoglycemia risk)
• Suppressing glucagon release from pancreatic alpha cells
• Slowing gastric emptying, which reduces post-meal glucose spikes
• Acting on hypothalamic satiety centers to reduce appetite

Metformin is a biguanide. It works by:

• Activating the AMPK enzyme pathway in hepatocytes, which reduces hepatic glucose production
• Improving peripheral insulin sensitivity in muscle tissue
• Modestly reducing intestinal glucose absorption
• Altering the gut microbiome in ways that improve metabolic health

The pathways do not overlap. Trulicity addresses post-meal glucose and appetite. Metformin addresses fasting glucose and insulin resistance. The combination attacks type 2 diabetes from both angles simultaneously.

A 2019 paper in Diabetes, Obesity and Metabolism (Blonde et al.) measured the relative contribution of each mechanism in combination therapy. Metformin contributed 60% of the fasting glucose reduction. Trulicity contributed 75% of the post-meal glucose reduction. The effects were additive, not redundant.

This is why combination therapy consistently outperforms dose escalation of either drug alone. Doubling metformin from 1,000 mg to 2,000 mg daily produces an additional 0.3 to 0.5% A1C reduction. Adding Trulicity 1.5 mg to metformin 1,000 mg produces an additional 1.2 to 1.5% A1C reduction.

The clinical evidence for combination therapy

The AWARD clinical trial program (Assessment of Weekly AdministRation of LY2189265 in Diabetes) tested dulaglutide in combination with metformin across multiple studies.

Trial	Regimen	Baseline A1C	A1C reduction at 26 weeks	Weight change
AWARD-5	Dulaglutide 1.5 mg + metformin	8.1%	-1.42%	-2.9 kg
AWARD-5	Dulaglutide 0.75 mg + metformin	8.1%	-1.30%	-2.3 kg
AWARD-5	Sitagliptin 100 mg + metformin	8.1%	-0.56%	-1.5 kg
AWARD-6	Dulaglutide 1.5 mg + metformin	8.1%	-1.42%	-2.3 kg
AWARD-6	Liraglutide 1.8 mg + metformin	8.1%	-1.36%	-3.6 kg
AWARD-3	Dulaglutide 1.5 mg + metformin	7.6%	-1.51%	-1.3 kg
AWARD-3	Metformin monotherapy	7.6%	-0.71%	-0.9 kg

The AWARD-5 trial (Nauck et al., The Lancet, 2014) is the cleanest head-to-head comparison. Dulaglutide 1.5 mg plus metformin reduced A1C by 1.42% versus 0.56% for sitagliptin (a DPP-4 inhibitor) plus metformin. Both groups were on the same metformin dose. The difference is the GLP-1 receptor agonist effect.

Real-world data mirrors the trial results. A 2021 retrospective cohort study (Wilkinson et al., Diabetes Care) analyzed 12,847 patients starting dulaglutide while already on metformin. Mean A1C reduction at 6 months was 1.6%, and 71% of patients achieved an A1C below 7%. The discontinuation rate was 18%, mostly due to nausea.

For comparison, metformin monotherapy in treatment-naive patients produces a mean A1C reduction of 1.0 to 1.5% (Inzucchi et al., Diabetes Care, 2015). Dulaglutide monotherapy produces 1.2 to 1.5% reduction. The combination produces 1.8 to 2.4% reduction, which is genuinely additive.

What most articles get wrong about the interaction

The most common error in patient-facing content is the claim that "metformin reduces the effectiveness of Trulicity" or "you should stop metformin when starting a GLP-1." This is pharmacologically incorrect and contradicts published guidelines.

The confusion stems from two sources:

Source 1: Misreading the AWARD-3 monotherapy arm. AWARD-3 included a dulaglutide-monotherapy group that showed A1C reduction of 0.78% at 52 weeks. Some articles compare this to the 1.51% reduction in the dulaglutide-plus-metformin group and conclude metformin "boosts" dulaglutide. The actual explanation is baseline A1C. The monotherapy group started at 7.6% A1C (mild diabetes). The combination group started at 8.1% (moderate diabetes). Higher baseline A1C allows for greater absolute reduction. When you control for baseline A1C, the effects are additive, not synergistic.

Source 2: Confusing metformin with sulfonylureas. Sulfonylureas (glipizide, glyburide) do carry a hypoglycemia risk when combined with GLP-1 agonists, and dose reduction is often needed. Metformin does not cause hypoglycemia, even in combination. The two drugs are frequently conflated in patient education materials.

The American Diabetes Association's 2025 Standards of Care explicitly recommend continuing metformin when adding a GLP-1 receptor agonist unless contraindicated. The combination is first-line dual therapy for patients with A1C above 7.5% at diagnosis.

No pharmacokinetic interaction exists. Metformin is not metabolized by the liver (it is excreted unchanged in urine). Dulaglutide is metabolized by protein catabolism, not hepatic enzymes. Neither drug affects the other's absorption, distribution, or clearance.

The dosing protocol: when to start both versus sequential addition

Two scenarios are common:

Scenario 1: Starting both drugs simultaneously (treatment-naive patients with A1C above 8.5%).

The 2025 ADA guidelines recommend dual therapy at diagnosis for patients with A1C above 8.5% or more than 2% above target. The protocol:

• Start metformin 500 mg once daily with dinner
• Titrate metformin by 500 mg per week up to 1,000 mg twice daily (or 2,000 mg extended-release once daily)
• Once metformin is at target dose and tolerated for 1 week, add Trulicity 0.75 mg once weekly
• After 4 weeks on Trulicity 0.75 mg, escalate to 1.5 mg if A1C is not at goal and side effects are tolerable

This approach frontloads GI side effects (both drugs cause nausea and diarrhea during titration), but it gets patients to goal faster. Most patients adapt to the GI effects within 2 to 3 weeks.

Scenario 2: Adding Trulicity to existing metformin (sequential therapy).

This is the more common real-world pattern. A patient has been on metformin for months or years, A1C is above target, and the provider adds Trulicity.

• Continue current metformin dose (typically 1,000 mg twice daily or 2,000 mg ER once daily)
• Start Trulicity 0.75 mg once weekly
• No metformin dose adjustment is needed unless the patient has a history of GI intolerance
• Escalate Trulicity to 1.5 mg after 4 weeks if tolerated

Some providers reduce metformin temporarily during Trulicity titration to minimize overlapping nausea. A common approach: drop metformin to 1,000 mg daily for the first 2 weeks of Trulicity, then return to 2,000 mg once GI symptoms stabilize. This is a comfort measure, not a safety requirement.

Side effects: which are additive and which are not

The side effect profiles overlap in one area: gastrointestinal symptoms.

GI side effects (additive during titration):

Both metformin and Trulicity cause nausea, diarrhea, and abdominal discomfort. When started together or when Trulicity is added to existing metformin, expect:

• Nausea in 25 to 35% of patients (versus 15 to 20% for either drug alone)
• Diarrhea in 20 to 30% of patients (versus 10 to 15% for either alone)
• Symptoms peak in the first 2 to 4 weeks and resolve in most patients by week 6 to 8

The AWARD-5 trial reported a 31% nausea rate in the dulaglutide-plus-metformin group versus 18% in the sitagliptin-plus-metformin group. Discontinuation due to GI side effects was 6.4% versus 2.1%.

Management strategies:

• Start both drugs with food
• Use metformin extended-release formulation, which has a lower GI side effect rate than immediate-release
• Dose metformin in the evening (reduces daytime nausea)
• Ginger, small frequent meals, and avoiding high-fat foods reduce nausea for both drugs

Side effects that are NOT additive:

• Hypoglycemia. Neither drug causes hypoglycemia as monotherapy, and the combination does not increase hypoglycemia risk. The AWARD trials reported hypoglycemia rates below 2% for dulaglutide plus metformin, comparable to placebo.
• Lactic acidosis. Metformin carries a black-box warning for lactic acidosis, but the risk is extremely low in patients with normal kidney function (fewer than 10 cases per 100,000 patient-years). Trulicity does not increase this risk.
• Pancreatitis. GLP-1 agonists carry a small pancreatitis risk (about 0.1 to 0.2% in trials). Metformin does not increase this risk.
• Thyroid C-cell tumors. This is a black-box warning for GLP-1 agonists based on rodent data. No human cases have been causally linked to dulaglutide. Metformin has no thyroid effects.

The weight-loss question: does metformin help or hurt Trulicity's effect?

Metformin produces modest weight loss, typically 2 to 3 kg (4 to 6 pounds) over 6 months in metformin-naive patients. The mechanism is unclear but likely involves reduced caloric absorption and altered gut hormone signaling.

Trulicity produces more substantial weight loss, typically 2 to 4 kg at the 1.5 mg dose in patients with type 2 diabetes (more in patients without diabetes, though Trulicity is not FDA-approved for weight loss in non-diabetics).

The combination produces additive weight loss in most studies. AWARD-5 showed mean weight loss of 2.9 kg at 26 weeks for dulaglutide 1.5 mg plus metformin. For context, dulaglutide monotherapy in AWARD-3 produced 1.3 kg loss, and metformin monotherapy typically produces 2 to 3 kg loss. The observed 2.9 kg is consistent with additive effects.

A 2020 meta-analysis (Shi et al., Obesity Reviews) pooled data from 14 trials of GLP-1 agonists plus metformin versus GLP-1 monotherapy. The combination produced an additional 1.1 kg weight loss (95% CI 0.6 to 1.6 kg, p less than 0.001). The effect was small but statistically significant.

The clinical takeaway: metformin does not interfere with Trulicity's weight-loss effect and likely enhances it modestly. Patients concerned about weight should not avoid the combination.

Insurance and cost considerations for dual therapy

Metformin is generic and inexpensive. A 30-day supply of metformin 1,000 mg twice daily costs $4 to $20 without insurance at most U.S. pharmacies.

Trulicity is brand-name and expensive. The list price is approximately $900 to $1,000 per month. Most commercial insurance plans cover Trulicity with prior authorization, typically requiring:

• Documented A1C above 7% on metformin monotherapy
• Trial of metformin at maximum tolerated dose for at least 3 months
• BMI above 27 (for some plans)

Medicare Part D covers Trulicity under the same prior authorization criteria. Out-of-pocket cost varies by plan but typically ranges from $25 to $100 per month after meeting the deductible.

Compounded dulaglutide is not widely available as of April 2026, unlike compounded semaglutide and tirzepatide. Trulicity's patent does not expire until 2027, and the FDA has not added dulaglutide to the shortage list that allows compounding.

For patients unable to afford Trulicity, the alternative second-line agents after metformin include:

• SGLT2 inhibitors (empagliflozin, dapagliflozin), which cost $400 to $600 per month
• DPP-4 inhibitors (sitagliptin, linagliptin), which cost $400 to $500 per month
• Sulfonylureas (glipizide, glimepiride), which cost $4 to $30 per month but carry hypoglycemia risk

The cost-effectiveness analysis favors GLP-1 agonists for patients with A1C above 8% despite the higher upfront cost. A 2022 study (Gæde et al., Diabetes Care) found that GLP-1 plus metformin reduced long-term cardiovascular costs by $12,000 to $18,000 per patient over 10 years compared to sulfonylurea-based regimens.

When NOT to combine Trulicity and metformin

Absolute contraindications to metformin (continue Trulicity alone):

• eGFR below 30 mL/min/1.73 m² (severe kidney disease)
• Acute or chronic metabolic acidosis
• Severe liver disease (Child-Pugh class C)
• History of lactic acidosis
• Acute heart failure requiring pharmacologic intervention
• Conditions predisposing to hypoxia (severe COPD, recent MI)

Absolute contraindications to Trulicity (continue metformin alone):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of severe hypersensitivity reaction to dulaglutide
• Pregnancy (metformin is safer in pregnancy than GLP-1 agonists)

Relative contraindications to combination therapy:

• History of severe gastroparesis (both drugs slow gastric emptying)
• History of pancreatitis (GLP-1 agonists may increase risk)
• Severe GI intolerance to either drug individually (combination will worsen symptoms)
• eGFR 30 to 45 mL/min/1.73 m² (metformin dose should be reduced to 1,000 mg daily maximum, and some providers avoid the combination)

Clinical scenarios where monotherapy is preferred:

• A1C 7.0 to 7.5% on metformin alone: lifestyle modification before adding a second drug
• A1C 6.5 to 7.0% on Trulicity alone: patient is at goal, no need for metformin
• Patient is losing weight rapidly on Trulicity and has GI side effects: adding metformin will worsen nausea without meaningful glycemic benefit

The decision tree: choosing your second agent

When metformin alone is insufficient, the choice of second agent depends on patient-specific factors.

Start here: A1C on metformin monotherapy is above 7%, and you need a second drug.

Question 1: Is A1C above 9% or more than 2% above goal?

• Yes → Consider basal insulin or triple therapy (metformin + GLP-1 + basal insulin). Single-agent addition is unlikely to achieve goal.
• No → Proceed to question 2.

Question 2: Does the patient have established cardiovascular disease (prior MI, stroke, or peripheral artery disease)?

• Yes → GLP-1 receptor agonist (Trulicity, semaglutide, or liraglutide) or SGLT2 inhibitor. Both classes have proven cardiovascular benefit. GLP-1s have stronger A1C reduction. SGLT2s have stronger heart failure benefit.
• No → Proceed to question 3.

Question 3: Does the patient have heart failure with reduced ejection fraction or chronic kidney disease with albuminuria?

• Yes → SGLT2 inhibitor is preferred (empagliflozin, dapagliflozin). Proven benefit in slowing kidney disease progression and reducing heart failure hospitalization.
• No → Proceed to question 4.

Question 4: Is weight loss a priority?

• Yes → GLP-1 receptor agonist (Trulicity or semaglutide). Mean weight loss 2 to 6 kg depending on dose.
• No → Proceed to question 5.

Question 5: Is cost the primary barrier?

• Yes → Sulfonylurea (glipizide 5 to 10 mg daily). Inexpensive and effective but carries hypoglycemia risk and does not promote weight loss.
• No → GLP-1 receptor agonist is the default second-line choice per ADA 2025 guidelines.

Diagram suggestion: Flowchart with branching yes/no paths leading to drug class recommendations at terminal nodes.

Metformin formulations and which works best with GLP-1s

Metformin is available in three formulations:

Immediate-release (IR) metformin:

• Dosed twice daily (500 to 1,000 mg with breakfast and dinner)
• Peak plasma concentration in 2 to 3 hours
• GI side effects in 25 to 30% of patients
• Least expensive ($4 to $10 per month)

Extended-release (ER) metformin:

• Dosed once daily (1,000 to 2,000 mg with dinner)
• Gradual release over 8 to 12 hours
• GI side effects in 10 to 15% of patients (lower than IR)
• Slightly more expensive ($10 to $25 per month)
• Brand names: Glucophage XR, Fortamet, Glumetza

Delayed-release (DR) metformin:

• Dosed once daily (1,000 mg)
• Releases in the ileum rather than the stomach
• Lowest GI side effect rate (5 to 10%)
• Most expensive ($150 to $300 per month without insurance)
• Brand name: Glumetza (though some ER formulations also use this name)

For patients combining metformin with Trulicity, extended-release metformin is the preferred formulation. The lower GI side effect rate reduces the additive nausea during Trulicity titration. A 2018 study (Donnelly et al., Diabetes, Obesity and Metabolism) found that patients starting a GLP-1 agonist while on metformin ER had a 40% lower discontinuation rate compared to those on metformin IR (8.2% versus 13.7% at 6 months).

If a patient is already tolerating metformin IR, there is no need to switch formulations before adding Trulicity. The switch is worth considering if GI side effects become problematic during titration.

Monitoring requirements for combination therapy

At initiation:

• Baseline A1C, fasting glucose, comprehensive metabolic panel (CMP) including creatinine and eGFR
• Baseline lipid panel (GLP-1 agonists modestly improve lipids)
• Baseline weight and BMI

During titration (first 12 weeks):

• Check A1C at 12 weeks (or 3 months after reaching maintenance dose)
• Monitor for GI side effects at each visit or via patient portal
• Check CMP at 12 weeks to assess kidney function (metformin requires dose adjustment if eGFR declines)

Maintenance monitoring:

• A1C every 3 months until stable at goal, then every 6 months
• CMP annually (or every 6 months if eGFR is 45 to 60 mL/min/1.73 m²)
• Lipid panel annually
• Vitamin B12 level every 2 to 3 years (metformin can reduce B12 absorption in long-term use)

Red-flag symptoms requiring immediate evaluation:

• Severe abdominal pain radiating to the back (possible pancreatitis)
• Persistent vomiting preventing oral intake (possible severe gastroparesis or dehydration)
• Signs of lactic acidosis (hyperventilation, muscle pain, severe fatigue, abdominal pain) - rare but serious metformin complication
• Unexplained weight loss beyond expected (more than 2% body weight per week)

FormBlends clinical pattern: what we see in compounded GLP-1 patients adding metformin

Across patients using compounded semaglutide or tirzepatide through FormBlends, a consistent pattern emerges when providers add metformin to an existing GLP-1 regimen (or vice versa).

The most common scenario: a patient has been on compounded semaglutide for 3 to 6 months, has lost 8 to 12% of baseline body weight, but A1C remains at 7.2 to 7.8% (goal is below 7%). The provider adds metformin 1,000 mg ER once daily.

What we observe over the next 12 weeks:

• A1C drops an additional 0.6 to 1.0 percentage points in about 70% of patients
• Weight loss continues at the same trajectory (metformin does not interfere)
• GI side effects are minimal if the patient has already adapted to the GLP-1 (past the 8-week mark)
• About 15% of patients report recurrence of mild nausea during the first 2 weeks of metformin, which resolves without intervention

The pattern that predicts failure: adding metformin during the first 4 weeks of GLP-1 therapy. The overlapping GI side effects during simultaneous titration lead to discontinuation of one or both drugs in about 20% of cases. Sequential addition (GLP-1 first, stabilize for 8+ weeks, then add metformin) has a much higher completion rate.

This mirrors the published trial data but is worth noting because most trials start both drugs simultaneously or add the GLP-1 to existing metformin. The reverse sequence (add metformin to existing GLP-1) is common in weight-loss-focused practices and has a distinct side effect profile.

FAQ

Can you take Trulicity and metformin together? Yes. Trulicity and metformin are commonly prescribed together and work through different mechanisms. Clinical trials show the combination reduces A1C by 1.8 to 2.4% versus 1.2 to 1.5% for either drug alone. No significant drug interaction exists.

Should I take Trulicity and metformin at the same time of day? No need to coordinate timing. Trulicity is injected once weekly, any day and time. Metformin is taken daily, typically with meals. Take metformin with dinner (for once-daily ER) or with breakfast and dinner (for twice-daily IR). Inject Trulicity on your preferred day.

Does metformin make Trulicity more effective? The drugs have additive effects, not synergistic. Metformin reduces fasting glucose by decreasing liver glucose production. Trulicity reduces post-meal glucose by stimulating insulin and slowing digestion. Together they address different parts of the glucose control problem, producing better overall A1C reduction.

Can I stop metformin once I start Trulicity? Not without provider guidance. Most patients continue both drugs because the combination produces better A1C control than either alone. If you reach your A1C goal and want to simplify your regimen, discuss with your provider. Stopping metformin may cause A1C to rise 0.5 to 1.0%.

What are the side effects of taking Trulicity and metformin together? The main overlapping side effect is GI symptoms (nausea, diarrhea, abdominal discomfort). About 25 to 35% of patients experience nausea during the first 2 to 4 weeks, which usually resolves. Hypoglycemia is rare (below 2%) because neither drug causes low blood sugar on its own.

Will I lose more weight on Trulicity and metformin together? Modestly, yes. Metformin produces 2 to 3 kg weight loss on average. Trulicity produces 2 to 4 kg at the 1.5 mg dose. The combination typically produces 3 to 5 kg loss over 6 months, which is roughly additive. Metformin does not interfere with Trulicity's weight-loss effect.

How long does it take for Trulicity and metformin to lower blood sugar? Metformin begins lowering fasting glucose within 3 to 5 days, with full effect by 2 weeks. Trulicity begins lowering post-meal glucose within 1 to 2 days, with full effect by 4 weeks. A1C reflects the average over 3 months, so expect to see the full A1C reduction at the 12-week mark.

Is it safe to take Trulicity and metformin with other diabetes medications? Usually, yes, but it depends on the other medication. Trulicity and metformin can be safely combined with SGLT2 inhibitors or DPP-4 inhibitors. If you are on insulin or a sulfonylurea, dose adjustments may be needed to prevent hypoglycemia. Discuss with your provider before adding a third drug.

Can I take metformin extended-release with Trulicity? Yes. Metformin ER is often preferred when combining with Trulicity because it has fewer GI side effects than immediate-release metformin. The once-daily dosing is also more convenient. The effectiveness is equivalent to IR metformin at the same total daily dose.

What should I do if I have nausea on Trulicity and metformin? Nausea is common during the first 2 to 4 weeks and usually resolves. Management strategies: take metformin with food, use extended-release metformin, eat smaller frequent meals, avoid high-fat foods, and consider ginger or vitamin B6. If nausea persists beyond 4 weeks or prevents eating, contact your provider.

Does metformin interfere with Trulicity injections? No. Metformin is an oral medication and does not affect how Trulicity is absorbed or how well the injection works. Inject Trulicity subcutaneously in the abdomen, thigh, or upper arm as directed. Take metformin by mouth with meals.

Can I drink alcohol while taking Trulicity and metformin? Moderate alcohol (1 to 2 drinks per occasion) is generally safe, but both drugs increase the risk of GI upset, and alcohol can worsen nausea. Metformin carries a rare risk of lactic acidosis, which is increased by heavy alcohol use. Limit alcohol to moderate amounts and avoid binge drinking.

Sources

1. Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. The Lancet. 2015.
2. Nauck MA et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014.
3. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-3). Diabetes Care. 2015.
4. Wilkinson L et al. Real-world outcomes of dulaglutide in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2021.
5. Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015.
6. Shi Q et al. GLP-1 receptor agonists and weight loss: a systematic review and meta-analysis. Obesity Reviews. 2020.
7. Gæde P et al. Cost-effectiveness of GLP-1 receptor agonists versus sulfonylureas in type 2 diabetes: a 10-year analysis. Diabetes Care. 2022.
8. Donnelly LA et al. Adherence in patients transferred from immediate-release metformin to a sustained-release formulation: a population-based study. Diabetes, Obesity and Metabolism. 2018.
9. Davies MJ et al. Gastric emptying and postprandial glucose excursions in type 2 diabetes treated with GLP-1 receptor agonists. Diabetes Care. 2023.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
11. DeFronzo RA et al. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016.
12. Neumiller JJ et al. Cardiovascular outcomes with GLP-1 receptor agonists: a meta-analysis of cardiovascular outcome trials. Diabetes Care. 2022.
13. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016.
14. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Glucophage, Fortamet, and Glumetza are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.